Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Mallinckrodt
AstraZeneca
McKesson

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Samatasvir

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Samatasvir?

Samatasvir is an investigational drug.

There have been 5 clinical trials for Samatasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2013.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Janssen Research & Development, LLC, and [disabled in preview].

There are two US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for Samatasvir
TitleSponsorPhase
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)Merck Sharp & Dohme Corp.Phase 1
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)Janssen Research & Development, LLCPhase 2
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)Merck Sharp & Dohme Corp.Phase 2

See all Samatasvir clinical trials

Clinical Trial Summary for Samatasvir

Top disease conditions for Samatasvir
Top clinical trial sponsors for Samatasvir

See all Samatasvir clinical trials

US Patents for Samatasvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Samatasvir   Start Trial 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors Idenix Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Samatasvir   Start Trial 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors Idenix Pharmaceuticals LLC (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Samatasvir

Drugname Country Document Number Estimated Expiration Related US Patent
Samatasvir Argentina 079528 2029-12-18   Start Trial
Samatasvir Australia 2010330862 2029-12-18   Start Trial
Samatasvir Brazil 112012014899 2029-12-18   Start Trial
Samatasvir Canada 2784748 2029-12-18   Start Trial
Samatasvir China 102822175 2029-12-18   Start Trial
Samatasvir European Patent Office 2513113 2029-12-18   Start Trial
Samatasvir Japan 2013514982 2029-12-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Baxter
Boehringer Ingelheim
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.